News about Global Pharma

ANI Pharmaceuticals to Acquire Alimera to Expand Rare Disease

ANI Pharmaceuticals, Inc. has announced that ANI will acquire Alimera for USD 5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to USD 0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

Global Pharma | 25/06/2024 | By Aishwarya |  819

Sun Pharma Announces Complete Acquisition of Taro

Sun Pharmaceutical Industries Ltd. has completed the merger of Taro Pharmaceutical Industries Ltd. with its subsidiary.

Global Pharma | 25/06/2024 | By Aishwarya |  808

Biocon Biologics Gets EMA Approval for Bevacizumab and its New mAbs Facility in India

Biocon Biologics Ltd. has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility in Bengaluru.

Global Pharma | 24/06/2024 | By Aishwarya |  1212

Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan

Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.

Global Pharma | 24/06/2024 | By Aishwarya |  1273

Lupin Gets EIR from US FDA for its Somerset Manufacturing Facility

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset.

Global Pharma | 24/06/2024 | By Aishwarya |  969

argenx Secures FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE

Halozyme Therapeutics has announced that argenx has received US Food and Drug Administration (FDA) approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy.

Global Pharma | 24/06/2024 | By Aishwarya |  713

Abzena and Argonaut to Offer End-to-End Drug Development Support for Biopharma Companies

Abzena has inked a strategic partnership with Argonaut Manufacturing Services, Inc. to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations.

Global Pharma | 21/06/2024 | By Aishwarya |  759

Johnson & Johnson Submits Application to US FDA Seeking Approval of TREMFYA

Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease.

Global Pharma | 21/06/2024 | By Aishwarya |  552

Regel Therapeutics Names Stephen J. Farr as New CEO

Regel Therapeutics’ Board of Directors has named Stephen J. Farr, PhD, as the new Chief Executive Officer (CEO).

Global Pharma | 21/06/2024 | By Aishwarya |  395

iOnctura Secures EUR 80 Million in Series B Financing Round

iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has closed a EUR 80 million Series B financing.

Global Pharma | 21/06/2024 | By Aishwarya |  763